Auto Injectors Market
Auto Injector is a medical device that is used to self-inject dose of drug, typically life-saving drugs. Auto injector keeps the needle tip covered before to inject and also has a safety mechanism to prevent accidental injection. Auto injectors are gaining importance these days to manage the severe conditions like anaphylaxis, rheumatoid arthritis, multiple sclerosis, and others. Most of the auto injectors are single dose and spring loaded syringes. The site of injection depends upon the drug loaded. Auto-Injectors are easy to use and intended for self-administration by patients or any other care taker or personnel at home.
Global auto injectors market is mainly driven by increase in incidence of the life threatening conditions such as anaphylaxis, multiple sclerosis and other food allergies that need an emergency medication. In addition, advancements in auto injectors like introduction of jet injectors, growing home healthcare segment, and increase in demand for the self-injectors expected to bolster the market growth. Furthermore, new formulations, new drug delivery systems, and advancements in targeted drug delivery systems, favourable government policies are expected to boost the auto injectors market. Many biologics are administered as intravenously hence, many manufacturers are adopting auto injectors for the life-saving biologics. However, stringent regulatory requirements, recent product recalls, and presence of substitute products are hampering the global auto injectors market.
Auto injectors market has been segmented based on type, technology, usability, distribution channel, and application
Based on type, auto injectors market is segmented into
Based on technology, auto injectors market is segmented into
Based on usability, auto injectors market is segmented into
Based on application, auto injectors market is segmented into
- Rheumatoid Arthritis
- Multiple Sclerosis
Based on distribution channel, auto injectors market is segmented into
- Retail Pharmacies
- Online Pharmacies
Auto injector manufacturers are diversifying the product portfolio by introducing low-cost auto injector products, incorporate advanced features into products, and with new product launches. For instance, Mylan N.V. introduced generic version of epipen by reducing the price to half of its original product price. Initial pack of two was sold at US$ 600 until December 2016 that will be sold at US$ 300 from January 2017. Bayer AG introduced betaconnect, an electronic auto injector to treat relapsing-remitting multiple sclerosis in 2016. Companies are actively involved in collaborations, and taking license agreements for auto injector’s technology. In September 2016, Aptar Pharma (AptarGroup, Inc.) collaborated with Becton, Dickinson and Company (BD) to develop auto injector using prefillable syringes from BD and Aptar Pharma’s two-step auto-injector technology.
Geographically global auto injectors market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to be a major market due to prevalence of anaphylaxis, favourable reimbursement policies and increase in healthcare expenditure. In Europe region, growth of auto injectors market is due to consumers shift from hospital based treatment to home care. Countries like China and India have huge growth potential due to increase in healthcare awareness, expenditure and regulatory initiatives to prevent needle stick injuries. However, various initiatives have been taken by World Health Organization (WHO) and regulatory agencies of the countries globally to create healthcare awareness and accelerate the adoption rate of auto-injectors in the Asia-Pacific region. The Middle East and Africa auto injectors market is expected to gain lucrative growth owing to increase in incidences of anaphylaxis and needle stick injuries due to poor healthcare practices in countries like South Africa.
Some of the players in global auto injectors market are Becton, Dickinson and Company (U.S), Sanofi (France), Pfizer, Inc. (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Bayer AG (Switzerland) , Johnson and Johnson Services Inc., (Janssen Global Services) (U.S.), Antares Pharma, Inc. (U.S.), Amgen Inc. (U.S.) and Eli Lilly and Company (U.S) to name a few.
- In March 2016, U.S. Food and Drug Administration (FDA) approved Eli Lilly’s Taltz (ixekizumab), auto injector to treat adults with moderate-to-severe plaque psoriasis.
- The report provides granular level information about the market size, regional market share and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario